MDGL
Madrigal Pharmaceuticals Inc
513.20$
+0.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | 95.9% | 95.5% | 88.4% | 86.9% | 95.4% | 93.8% | 91.1% | 95.3% | 95.2% | 98.4% | 96.9% | 98.7% | 0.5% | 100.0% | 99.8% | 100.0% | 99.6% | 99.4% | 99.4% | 99.7% | 99.5% | 99.1% | 98.9% | |
| – | – | 44.9% | 32.4% | 33.4% | 61.5% | 94.2% | 53.5% | 90.3% | 57.9% | 71.1% | 79.1% | 50.9% | 45.7% | 51.3% | 98.3% | 77.3% | 11.8% | 10.6% | 18.8% | 13.3% | 91.4% | 15.6% | 9.6% | 15.8% | |
| – | – | 94.8% | 94.7% | 87.1% | 85.5% | 94.2% | 75.6% | 90.3% | 94.3% | 93.9% | 97.7% | 96.1% | 97.0% | 97.6% | 98.3% | 99.6% | 99.6% | 99.3% | 99.0% | 98.9% | 99.0% | 99.0% | 88.9% | 78.1% | |
| – | – | – | – | – | – | – | 16.5% | – | 0.2% | – | – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | 0.0% | 5.2% | 10.7% | |
| – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | 0.0% | 3.3% | 5.9% | |
| – | – | – | – | – | – | – | – | – | – | 3.3% | 1.1% | 0.0% | 0.0% | 0.6% | 0.0% | 0.2% | 0.0% | 0.3% | 0.4% | 0.6% | 0.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | 0.5% | 0.6% | |
| 1.0% | – | 4.3% | 10.7% | 26.3% | 103.2% | 79.7% | 160.5% | 49.1% | 56.6% | 65.1% | 27.1% | 48.4% | 35.3% | 26.1% | 11.6% | 5.2% | 1.7% | 5.8% | 16.4% | 28.3% | 45.6% | 36.7% | 27.6% | 52.2% | |
| – | – | 4.3% | 9.8% | 20.3% | 21.1% | 16.9% | 34.3% | 33.7% | 31.0% | 35.8% | 22.8% | 33.8% | 30.7% | 72.3% | 11.6% | 5.2% | 1.7% | 5.7% | 16.2% | 28.1% | 32.0% | 18.5% | 16.2% | 24.6% | |
| – | – | – | 0.4% | 2.7% | 4.3% | 2.0% | 4.5% | 2.6% | 0.4% | 10.0% | 7.7% | 10.0% | 9.2% | 72.0% | – | – | – | 0.1% | 0.1% | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% | |
| – | – | 0.3% | 2.2% | 4.7% | 4.8% | 2.0% | 3.4% | 8.1% | 3.6% | 8.2% | 5.5% | 6.9% | 3.1% | 0.2% | 1.8% | 1.0% | 0.5% | 0.3% | 0.4% | 7.8% | 6.6% | 4.4% | 4.2% | 3.9% | |
| – | – | – | – | – | – | – | – | – | – | 29.3% | 4.3% | 0.0% | 41.9% | 0.0% | 0.0% | 0.0% | – | – | – | – | 13.6% | 18.0% | 11.3% | 27.0% | |
| 99.0% | – | 95.7% | 89.3% | 73.7% | -3.2% | 20.3% | -60.5% | 50.9% | 43.4% | 34.9% | 72.9% | 51.6% | 64.7% | 73.9% | 88.4% | 94.8% | 98.3% | 94.2% | 83.6% | 71.7% | 54.4% | 63.3% | 72.4% | 47.8% | |
| – | – | -80.2% | -83.6% | -251.8% | -431.8% | -244.6% | -403.8% | -641.1% | -649.3% | -941.4% | -447.7% | -579.2% | -633.3% | -1,035.6% | -182.7% | -55.4% | -28.7% | -50.5% | -148.2% | -244.1% | -265.5% | -208.6% | -172.9% | -166.0% | |
| 3.0% | – | 0.8% | 0.4% | 0.9% | 1.2% | 0.8% | 1.0% | 2.0% | 2.1% | 3.2% | 1.6% | 2.1% | 2.8% | 0.3% | 12.6% | 6.4% | 3.0% | 3.5% | 5.4% | 6.0% | 4.7% | 2.9% | 2.0% | 1.8% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.